World.- A team from the Beijing Institute of Biotechnology and Chinese firm Cansino Biologics has announced promising results in phase 1 of their vaccine with 108 healthy adults, after 28 days of trials. According to the authors, the new vaccine is safe, well tolerated and capable of generating antibodies against SARS-CoV-2 in humans. The final results will be evaluated in six
The race to get a COVID-19 vaccine continues at a frenetic pace. The latest announcement was made by a team from the Beijing Institute of Biotechnology (China) and the company Cansino Biologics, which has published in The Lancet a study in which he claims to have achieved promising results in phase 1 of his vaccine with 108 healthy adults, after 28 days of trials.
The new vaccine is safe, well tolerated and able to generate an immune response against SARS-CoV-2 in humans, according to the authors
The authors note that the new vaccine is safe, well tolerated and capable of generating an immune response against SARS-CoV-2 in humans. The final results will be evaluated in six months.
The announcement by Chinese researchers is in addition to those made last week by US biotechnology firm Moderna, which said it had obtained positive interim data in phase 1 of its coronavirus vaccine. For its part, the University of Oxford reported that its vaccine was progressing towards phases 2 and 3 and that it would be tested in more than 10,000 people including children and over 70 years old.
As Wei Chen, the first author and leader of the study, points out, “these results represent an important milestone. The trial shows that a single dose of the new COVID-19 vaccine vectorized by adenovirus type 5 [Ad5-nCoV] produces specific antibodies against the virus and T cells in 14 days, making it a possible candidate for further investigation.”
However, the epidemiologist adds that “these results should be interpreted with caution, as challenges in the development of a COVD-19 vaccine are unprecedented, and the ability to trigger these immune response does not necessarily indicate that it will protect against coronavirus. We’re still a long way from making this vaccine available to everyone.”
“The results should be interpreted with caution. The ability to trigger immune response does not necessarily indicate that it will protect against coronavirus. We’re still a long way from the vaccine making the vaccine available to everyone,” says the study leader
Tests with different doses
The new Ad5-vectorized COVID-19 vaccine evaluated in this trial uses a weakened common cold virus – adenovirus, which easily infects human cells but is unable to cause disease – to introduce into cells the genetic material that encodes proteins into the form of a spiculate with which SARS-CoV-2 enters cells. These cells then produce the spur protein and travel to the lymph nodes, where the immune system creates antibodies that recognize that protein and fight the coronavirus.
The trial assessed the safety and ability to generate an immune response of different doses of the new Ad5-nCoV vaccine in 108 healthy adults between 18 and 60 years of age who were not infected with SARS-CoV-2.
The creation of an effective vaccine is considered the long-term solution to control the COVID-19 pandemic. Currently, there are more than 100 candidate vaccines for COVID-19 under development worldwide.
Source: SINC
